- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01195454
Euglycemic Clamp Dose-response Study Comparing a New Insulin Glargine Formulation With Lantus®
Primary Objective:
- To assess the total metabolic effect ratios of a new insulin glargine formulation versus Lantus®
Secondary Objectives:
- To assess the exposure ratios of a new insulin glargine formulation versus Lantus®
- To compare the duration of action of a new insulin glargine formulation versus Lantus®
- To explore the dose response and dose exposure relationship of a new insulin glargine formulation
- To assess the safety and tolerability of a new insulin glargine formulation
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The study period for one patient is one month in average and it can last up to 11 weeks broken down as follows:
- Screening: 3 to 28 days
- Treatment period: 1 to 4 days: 2 days (1 overnight stay)
- Washout period: 5 to 18 days (preferentially 7 days between consecutive dosings)
- End of study: 1 day after the last dosing
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
-
Berlin, Germany
- Sanofi-Aventis Administrative Office
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion criteria:
- Male or female subjects with diabetes mellitus type 1 for more than one year,
- Total insulin dose of <1.2 U/kg/day,
- Glycohemoglobin (HbA1c) ≤ 9.0%,
- Fasting negative serum C-peptide (< 0.3 nmol/L),
- Stable insulin regimen for at least 2 months prior to study,
- Normal findings in medical history and physical examination (cardiovascular system, chest and lungs, thyroid, abdomen, nervous system, skin and mucosae, and musculo-skeletal system), vital signs, electrocardiogram (ECG) and safety lab,
- Women of childbearing potential with negative pregnancy test and use of a highly effective contraceptive method or women with confirmed postmenopausal status.
Exclusion criteria:
- Any history or presence of clinically relevant cardiovascular, pulmonary, gastro-intestinal, hepatic, renal, metabolic (apart from diabetes mellitus type 1), hematological, neurological, psychiatric, systemic (affecting the body as a whole), ocular, gynecologic (if female), or infectious disease; any acute infectious disease or signs of acute illness,
- More than one episode of severe hypoglycemia with seizure, coma or requiring assistance of another person during the past 6 months,
- Frequent severe headaches and / or migraine, recurrent nausea and / or vomiting (more than twice a month),
- Symptomatic hypotension (whatever the decrease in blood pressure), or asymptomatic postural hypotension defined by a decrease in SBP equal to or greater than 20 mmHg within three minutes when changing from the supine to the standing position,
- Presence or history of a drug allergy or clinically significant allergic disease,
- Likelihood of requiring treatment during the study period with drugs not permitted by the clinical study protocol,
- Pregnant or breast feeding women,
- Any medication (including St John's Wort) within 14 days before inclusion, or within 5 times the elimination half-life or pharmacodynamic half-life of that drug, whichever the longest and regular use of any medication other than insulins in the last month before study start with the exception of thyroid hormones, lipid-lowering and antihypertensive drugs, and, if female, with the exception of hormonal contraception or menopausal hormone replacement therapy; any vaccination within the last 28 days,
- Positive reaction to any of the following tests: hepatitis B surface (HBs Ag) antigen, antihepatitis B core antibodies (anti-HBc Ab) if compound having possible immune activities, anti-hepatitis C virus (anti-HCV2) antibodies, anti-human immunodeficiency virus 1 and 2 antibodies (anti-HIV1 and anti HIV2 Ab),
- Known hypersensitivity to insulin glargine and excipients,
- Any history or presence of deep leg vein thrombosis.
The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Insulin glargine / New insulin glargine formulation
Duration of treatment: 1 day at each period |
Pharmaceutical form: Lantus solution for injection Route of administration: subcutaneous Pharmaceutical form: New insulin glargine formulation solution for injection Route of administration: subcutaneous |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
The area under the body weight standardized glucose infusion rate curve (GIR) within 36 hours (GIR-AUC0-36)
Time Frame: 36 hours (D1 to D2) in all four treatment periods
|
36 hours (D1 to D2) in all four treatment periods
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
The area under the insulin glargine concentration curve within 36 hours (INS-AUC0-36) -
Time Frame: 36 hours (D1 to D2) in all four treatment periods
|
36 hours (D1 to D2) in all four treatment periods
|
Time to 50% of the GIR-AUC0-36 (T50%-GIR AUC0-36)
Time Frame: 36 hours (D1 to D2) in all four treatment periods
|
36 hours (D1 to D2) in all four treatment periods
|
Time to 50% of INS-AUC0-36 (T50% INS-AUC0-36)
Time Frame: 36 hours (D1 to D2) in all four treatment periods
|
36 hours (D1 to D2) in all four treatment periods
|
Duration of blood glucose control (time to elevation of smoothed blood glucose profile above clamp level and to elevation above different pre-specified blood glucose levels)
Time Frame: 36 hours (D1 to D2) in all four treatment periods
|
36 hours (D1 to D2) in all four treatment periods
|
Maximum smoothed body weight standardized glucose infusion rate GIRmax, and time to GIRmax (GIR-Tmax)
Time Frame: 36 hours (D1 to D2) in all four treatment periods
|
36 hours (D1 to D2) in all four treatment periods
|
Maximum insulin concentration INS-Cmax, and time to Cmax (INS-Tmax)
Time Frame: 36 hours (D1 to D2) in all four treatment periods
|
36 hours (D1 to D2) in all four treatment periods
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- PKD11627
- 2010-020914-27 (EudraCT Number)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Type 1 Diabetes Mellitus
-
SanofiCompletedType 1 Diabetes Mellitus-Type 2 Diabetes MellitusHungary, Russian Federation, Germany, Poland, Japan, United States, Finland
-
University of Colorado, DenverMassachusetts General Hospital; Beta Bionics, Inc.CompletedDiabetes Mellitus, Type 1 | Type 1 Diabetes | Diabetes type1 | Type 1 Diabetes Mellitus | Autoimmune Diabetes | Diabetes Mellitus, Insulin-Dependent | Juvenile-Onset Diabetes | Diabetes, Autoimmune | Insulin-Dependent Diabetes Mellitus 1 | Diabetes Mellitus, Insulin-Dependent, 1 | Diabetes Mellitus, Brittle | Diabetes Mellitus, Juvenile-Onset and other conditionsUnited States
-
AstraZenecaCompletedType 2 Diabetes Mellitus | Type 1 Diabetes MellitusUnited States
-
University of California, San FranciscoJuvenile Diabetes Research FoundationCompletedType 1 Diabetes Mellitus | Diabetes Mellitus, Type I | Insulin-Dependent Diabetes Mellitus 1 | Diabetes Mellitus, Insulin-Dependent, 1 | IDDMUnited States, Australia
-
Capillary Biomedical, Inc.TerminatedType 1 Diabetes | Type 1 Diabetes Mellitus | Diabetes Mellitus, Type I | Diabetes Mellitus, Insulin-Dependent, 1 | IDDMAustria
-
National Institute of Allergy and Infectious Diseases...PPD; Rho Federal Systems Division, Inc.; Immune Tolerance Network (ITN)CompletedType 1 Diabetes Mellitus | T1DM | T1D | New-onset Type 1 Diabetes MellitusUnited States, Australia
-
Capillary Biomedical, Inc.CompletedDiabetes Mellitus, Type 1 | Type 1 Diabetes | Type 1 Diabetes Mellitus | Diabetes Mellitus, Insulin-Dependent, 1Australia
-
Shanghai Changzheng HospitalRecruitingBrittle Type 1 Diabetes MellitusChina
-
Spiden AGDCB Research AGCompletedType 1 Diabetes Mellitus | Type 1 Diabetes Mellitus With Hypoglycemia | Type 1 Diabetes Mellitus With HyperglycemiaSwitzerland
-
Instytut Diabetologii Sp. z o.o.National Center for Research and Development, Poland; Nalecz Institute of Biocybernetics...UnknownType 1 Diabetes Mellitus With Hyperglycemia | Type 1 Diabetes Mellitus With HypoglycaemiaPoland
Clinical Trials on Insulin glargine (HOE901)
-
SanofiCompleted
-
SanofiTerminated
-
SanofiCompleted
-
SanofiCompleted
-
SanofiCompletedType 1 Diabetes MellitusJapan
-
SanofiCompleted
-
SanofiCompletedType 2 Diabetes MellitusUnited States, Australia, Spain, Korea, Republic of, Hungary, Mexico, Italy, Poland, Argentina, Canada, Colombia, France, Germany, Japan, Peru, Romania, Sweden, United Kingdom
-
SanofiCompleted
-
SanofiCompletedType 2 Diabetes MellitusChina, Taiwan, Korea, Republic of